Keyphrases
Adverse Events
9%
Autism Spectrum Disorder
13%
Breast Cancer Patients
12%
Clinical Benefit
19%
Clinical Database
10%
Clinical Features
17%
Clinical Risk
16%
Clinical Seizure
8%
Confidence Interval
10%
Disease Risk
16%
Disease Transmission
16%
Electroencephalography
10%
Electroencephalography Activity
9%
Epilepsy
19%
Epilepsy Outcome
16%
Epileptiform
13%
Everolimus
10%
Excel
8%
Fetal Brain Magnetic Resonance Imaging
8%
In Cancer
10%
Ipilimumab
16%
Leptomeningeal Carcinomatosis
8%
Low-level Mosaicism
16%
Metastatic Breast Cancer
9%
Metastatic RCC
14%
Metastatic Renal Cell Carcinoma (mRCC)
82%
Middle East
9%
MTOR Inhibitor
9%
MTOR Pathway
13%
Neurodevelopment
10%
Neurodevelopmental Outcome
24%
Non-aspirin Non-steroidal Anti-inflammatory Drugs
8%
Overall Survival
11%
Pathogenic Variants
11%
Pathway Genes
12%
Poor Risk
8%
Prospective Cohort Study
9%
Rapalogs
24%
Renal Cell Carcinoma
15%
Seizure
10%
Signet Ring
8%
Single nucleotide Polymorphism
8%
Sunitinib
12%
Survival Outcomes
8%
Systemic Therapy
12%
Targeted Therapy
22%
Transmission Genetics
8%
TSC1
25%
Tuberous Sclerosis Complex
100%
Young Age
9%
Medicine and Dentistry
Adverse Event
7%
Cancer Pathobiology
8%
Cancer Stem Cell
8%
Cancer Treatment
9%
Cell-Free DNA
8%
Clear Cell Renal Cell Carcinoma
17%
Clinical Feature
10%
Colorectal Carcinoma
8%
Disease
13%
DNA Determination
8%
DNA Methylation
8%
Electroencephalogram
8%
Epileptic Seizure
12%
Erythrocyte
8%
Everolimus
10%
Glycon
8%
Horizontal Disease Transmission
8%
Immune-Related Adverse Events
8%
Immune-Related Gene
8%
Immunotherapy
8%
Ipilimumab
16%
Kidney Metastasis
65%
Lenvatinib
8%
Magnetic Resonance Imaging
20%
Malignant Neoplasm
14%
Mammalian Target of Rapamycin
16%
Mammalian Target of Rapamycin Inhibitor
9%
Medicine
8%
Metastatic Carcinoma
12%
Metastatic Melanoma
8%
Microcirculation
8%
Mosaicism
14%
Neoplasm
23%
Nerve Cell Differentiation
8%
PARP Inhibitor
8%
Pharmacogenomics
8%
Prevalence
16%
Programmed Death-Ligand 1
8%
Prospective Cohort Study
8%
Single Nucleotide Polymorphism
8%
Sprouting Angiogenesis
8%
Sunitinib
10%
Surgery
9%
Systemic Therapy
12%
Targeted Therapy
19%
Tertiary Care
8%
Tuberous Sclerosis
49%
Tumor Cell
8%
Tumor Microcirculation
8%
Tyrosine-Kinase Inhibitor
8%
